Table 1.
Baseline demographic and clinical characteristics of the patients
| Patients | ||||
|---|---|---|---|---|
| Characteristics | N | Percentage | ||
| Patient’s numbers | 48 | 100% | ||
| Sex | ||||
| Female | 20 | 42% | ||
| Male | 28 | 58% | ||
| Age (years)* | 77 (40–86) | |||
| Acute Leukemia Myeloid | ||||
| Primary | 24 | 50% | ||
| Secondary | 24 | 50% | ||
| MRC | 12 | 50% | ||
| Chemotherapy | 12 | 50% | ||
| European Leukemia Network | ||||
| Favorable | 2 | 4% | ||
| Intermediate | 9 | 19% | ||
| Adverse | 37 | 77% | ||
| Karyotype | ||||
| Normal | 24 | 50% | ||
| Monosomic | 9 | 19% | ||
| Complex | 15 | 31% | ||
| Mutations | ||||
| FLT3 | 10 | 21% | ||
| IDH1 | 2 | 4% | ||
| IDH2 | 7 | 14% | ||
| NRAS | 3 | 6% | ||
| KRAS | 1 | 2% | ||
| NPM1 | 8 | 17% | ||
| TP53 | 13 | 27% | ||
| Treatment lines | ||||
| First line | 33 | 69% | ||
| Second line or more | 15 | 31% | ||
| Baseline blood cells | ||||
| Hemoglobin* | 85.5 (62–124) | |||
| Platelets* | 53 (6-356) | |||
| Neutrophil* | 0.6 (0-10.2) | |||
| White blood cell* | 2.8 (0.6–42.1) | |||
| Bone marrow blasts (%) | ||||
| ≤ 30% | 17 | 38% | ||
| ]30%; 50%] | 10 | 22% | ||
| > 50% | 18 | 40% | ||
| Median* | 42 (8–98) | |||
| Baseline cytopenia grade ≥ 3 | ||||
| Anemia | 12 | 25% | ||
| Thrombopenia | 23 | 48% | ||
| Neutropenia | 28 | 58% | ||
*Median (Minimum-Maximum)